Privately-held biopharma Tizona Therapeutics Inc. got its New Year off to a good start by unveiling an early-stage cancer R&D collaboration with AbbVie Inc. by which the San Francisco-based biotech will receive a $105m upfront cash payment plus an equity injection from the big pharma.
News of the R&D pact - aimed at inhibiting the activity of CD39 - coincides with the arrival at Tizona...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
